Sun Pharmaceutical industries share price has declined 4-5% in 2 trading sessions following OAI status determined by the ...
Regulatory troubles continue for Sun Pharma as the drug manufacturer’s ... Analysts at HSBC expect the FDA move to add to the regulatory overhang for the drugmaker, while those at Nomura ...
The US Food and Drug Administration (US FDA) has released a detailed report ... the regulator to achieve fully compliant status,” Sun Pharma had informed exchanges on the matter on April 11.
The Sun Pharma's ordeal with the US drug regulator continues as its Halol Manufacturing facility in Gujarat is already under USFDA scanner facing import alert. Its Mohali unit also swaits USFDA ...
Advt Drug sales in India, which account for over 31 per cent of Sun Pharma's total consolidated ... the U.S. Food and Drug Administration's import alert in December at a plant in Gujarat, without ...
“These products pose unacceptable risks to consumers and should not be on the market,” said Jill Furman, J.D., director of the Office of Compliance in the FDA ... on import alert to help ...
New Delhi: On 18 April, Mumbai-headquartered Marksans Pharma, a drugmaker that ... from ThePrint on the status of this alert, the US FDA said that “in order for FDA to consider removing a product ...
Sun Pharma said that the US FDA conducted an inspection at the company's Dadra facility from December 4, 2023 to December 15, 2023. The US FDA has subsequently determined the inspection ...
The Food and Drug Administration published an expanded import alert Wednesday to stop all plastic syringes made by a Chinese manufacturer from entering the U.S. On March 28, the FDA issued an ...
The Food and Drug Administration published an expanded import alert Wednesday to stop all plastic syringes made by a Chinese manufacturer from entering the U.S. On March 28, the FDA issued an ...